Literature DB >> 15742615

Veterinary vaccines for animal and public health.

P P Pastoret1, P Jones.   

Abstract

Vaccination is without doubt the most useful single measure available to prevent animal infectious diseases. The advantages of vaccination are numerous. It is the only available method to prevent, or sometimes cure, viral animal infections in the absence of broad spectrum antivirals and avoids the alternative of mass slaughtering of livestock. Antibiotic or anthelmintic resistance, and the problem of pharmaceutical residues, promote the use of vaccines rather than chemotherapy. Vaccines are environmentally friendly and increase animal welfare by preventing suffering from disease resulting from treatment for a cure which may result in antibiotic resistance and pharmaceutical residues in food. For the management of livestock health vaccines are the best tool to achieve sustainability. Veterinary vaccines cannot only be used to protect animal health but also human health from zoonotic infections through animal vaccination as exemplified by wildlife vaccination against rabies. In animal health the focus is now on animal infections rather than on animal diseases. Vaccines should be designed to prevent infection rather than to prevent clinical signs of disease and should, wherever possible, produce sterile immunity. Available technologies allow us to design "marker" vaccines together with their companion diagnostic tests which permit the distinction between vaccinated and infected animals even if the latter were previously vaccinated. Examples will be given of foot-and-mouth disease, classical swine fever, and herpesvirus infections of livestock such as pseudorabies or infectious bovine rhinotracheitis where carrier state or latency remain an issue after vaccination.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15742615

Source DB:  PubMed          Journal:  Dev Biol (Basel)        ISSN: 1424-6074


  8 in total

Review 1.  Current status of veterinary vaccines.

Authors:  Els N T Meeusen; John Walker; Andrew Peters; Paul-Pierre Pastoret; Gregers Jungersen
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

Review 2.  From the bluetongue vaccination campaigns in sheep to overimmunization and ovine ASIA syndrome.

Authors:  J Asín; M Pérez; P Pinczowski; M Gimeno; L Luján
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

Review 3.  Vaccine adjuvants: current challenges and future approaches.

Authors:  Jennifer H Wilson-Welder; Maria P Torres; Matt J Kipper; Surya K Mallapragada; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

4.  A gaps-and-needs analysis of vaccine R&D in Europe: Recommendations to improve the research infrastructure.

Authors:  Stefan Jungbluth; Hilde Depraetere; Monika Slezak; Dennis Christensen; Norbert Stockhofe; Laurent Beloeil
Journal:  Biologicals       Date:  2022-02-26       Impact factor: 1.760

Review 5.  Effectiveness and profitability of preventive veterinary interventions in controlling infectious diseases of ruminant livestock in sub-Saharan Africa: a scoping review.

Authors:  Francis Sena Nuvey; Jalil Arkoazi; Jan Hattendorf; Gloria Ivy Mensah; Kennedy Kwasi Addo; Günther Fink; Jakob Zinsstag; Bassirou Bonfoh
Journal:  BMC Vet Res       Date:  2022-09-02       Impact factor: 2.792

Review 6.  Safety and Efficacy Profile of Commercial Veterinary Vaccines against Rift Valley Fever: A Review Study.

Authors:  Moataz Alhaj
Journal:  J Immunol Res       Date:  2016-09-04       Impact factor: 4.818

Review 7.  Emerging diseases, zoonoses and vaccines to control them.

Authors:  Pastoret Paul-Pierre
Journal:  Vaccine       Date:  2009-06-24       Impact factor: 3.641

8.  An effective inactivant based on singlet oxygen-mediated lipid oxidation implicates a new paradigm for broad-spectrum antivirals.

Authors:  Lei Zeng; Meng-Di Wang; Sheng-Li Ming; Guo-Li Li; Peng-Wei Yu; Yan-Li Qi; Da-Wei Jiang; Guo-Yu Yang; Jiang Wang; Bei-Bei Chu
Journal:  Redox Biol       Date:  2020-06-08       Impact factor: 11.799

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.